Nonmelanoma Skin Cancer
From the Journals
Tattoo artist survey finds almost half agree to tattoo skin with lesions
What role do dermatologist play in the tattoo industry, when two-thirds of tattoo artists reported having no official policy regarding tattooing...
Conference Coverage
Merkel cell carcinoma most likely to recur within 2 years of diagnosis
PORTLAND, ORE. - For the first time, a retrospective study provides information to help answer patient's questions about recurrence of MCC.
From the Journals
Reflectance confocal microscopy offers one-stop solution for BCC
Reflectance confocal microscopy was found noninferior to the standard approach to treating basal cell carcinoma.
Conference Coverage
Avelumab produces durable responses in Merkel cell carcinoma
“Avelumab could be an important new agent for patients with Merkel cell carcinoma who have failed prior chemotherapy,” said Dr. Howard L. Kaufman...
News
FDA approves first treatment for metastatic Merkel cell carcinoma
A newly approved drug may help the body’s immune system attack metastatic MCC cells.
From the Journals
Racial differences in skin cancer risk after organ transplantation
Do dermatologists need to consider patients’ race when doing organ transplants?
From the Journals
Immune-suppressing drugs in IBD linked to higher skin cancer rates
Immune-suppressing drugs may cause skin cancer, according to a new Irish study that links immunomodulator use in younger patients with...
From the Journals
Skin cancer a concern in pediatric solid organ transplant recipients
As survival rates among pediatric organ transplant recipients grow, so do the rates of cutaneous malignancy later in life for this population, who...
From the Journals
Azathioprine linked to increased risk of SCC in transplant recipients
Immunosuppressive treatment with azathioprine may be associated with an increased risk of squamous cell carcinoma in organ transplant recipients,...
From the Journals
Study finds 19% of Merkel cell carcinomas are virus negative
Such cancers are substantially more aggressive than those that are virus positive.
News
Matrilin-2 protein distinguished BCCs from benign tumors in study
Key clinical point: Matrilin-2 is the first marker of tumor invasion to be used in skin cancers. Major finding: The protein bound to 41 of 42 BCCs...